HIV状态和疫苗接种程序对南非婴儿接种肺炎球菌不可分型流感嗜血杆菌蛋白D结合疫苗后细菌鼻咽携带的影响
这项III期开放单中心对照研究纳入484名南非儿童,按HIV状态分层为HIV阳性83名、HIV暴露未感染101名和HIV未暴露未感染300名,评估接种肺炎球菌不可分型流感嗜血杆菌蛋白D结合疫苗后鼻咽部肺炎链球菌及其他病原体携带情况。结果显示HIV感染或暴露似乎不改变疫苗对2岁内儿童肺炎球菌鼻咽携带的影响,接受加强剂的儿童疫苗型肺炎球菌携带率倾向于更低。
要点
- HIV感染或暴露似乎不改变PHiD-CV对2岁内儿童肺炎球菌鼻咽携带的影响。
- HIV阳性组在24-27月龄时肺炎球菌携带率有高于HIV暴露未感染组和HIV未暴露未感染3+1组的趋势。
- HIV未暴露未感染儿童中,接受加强剂组在16-19和24-27月龄时疫苗型肺炎球菌携带率倾向于低于未接受加强剂组。
核心结论
- HIV感染或暴露似乎不改变PHiD-CV对儿童出生后2年内肺炎球菌鼻咽携带的影响。
- 接种程序后疫苗型肺炎球菌鼻咽携带率在接受加强剂者中倾向于低于未接受加强剂者。
研究设计与样本
- III期开放单中心对照研究(ClinicalTrials.gov: NCT00829010),共纳入484名南非儿童。
- 按HIV状态分层:HIV阳性83名、HIV暴露未感染101名、HIV未暴露未感染300名。
- HIV阳性和HIV暴露未感染儿童接受3+1剂PHiD-CV程序:6/10/14周龄基础免疫,9-10月龄加强剂。
- HIV未暴露未感染婴儿按1:1:1随机分为3剂基础免疫加加强剂(HUU/3+1)、3剂基础免疫无加强剂(HUU/3+0)或2剂基础免疫加加强剂(HUU/2+1)。
- 至24-27月龄期间共评估8次细菌鼻咽携带。
主要发现
- 无论HIV状态如何,3+1组间总体肺炎球菌携带率相似。
- 在24-27月龄时,HIV阳性组肺炎球菌携带率有高于HIV暴露未感染组和HUU/3+1组的趋势。
- HIV未暴露未感染儿童中,三种接种程序的任何肺炎球菌血清型携带率在所有时间点相似。
- 在16-19月龄和24-27月龄时,接受加强剂的HUU/2+1和HUU/3+1组疫苗型肺炎球菌携带率倾向于低于HUU/3+0组。
- 不可分型流感嗜血杆菌、金黄色葡萄球菌和卡他莫拉菌的携带率在所有组间相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nasopharyngeal carriage (NPC) of Streptococcus pneumoniae is a precondition for pneumococcal disease and a source of transmission. This trial evaluated NPC of S. pneumoniae and other pathogens post-vaccination with the pneumococcal non-typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine (PHiD-CV) in human immunodeficiency virus (HIV)-infected (HIV+), HIV-exposed-uninfected (HEU), and HIV-unexposed-uninfected (HUU) South African children. METHODS: In this phase III, open, single-centre, controlled study (ClinicalTrials.gov: NCT00829010), 484 children were stratified by HIV status: 83 HIV+, 101 HEU, and 300 HUU. HIV+ and HEU children received a 3 + 1 PHiD-CV vaccination schedule: primary vaccination, age 6/10/14 weeks, and booster dose, age 9-10 months. HUU infants were randomised (1:1:1) to 3-dose priming and booster (HUU/3+1); 3-dose priming without booster (HUU/3+0); or 2-dose priming and booster (HUU/2+1). Bacterial NPC was assessed 8 times up to 24-27 months of age. RESULTS: Overall pneumococcal carriage rates were similar across 3+1 groups irrespective of HIV status; trends towards higher carriage rates in the HIV+ than HEU and HUU/3+1 groups were observed at 24-27 months of age. In HUU children, carriage of any pneumococcal serotype was similar for the three different dosing schedules at all timepoints; carriage of vaccine-type pneumococci tended to be lower at 16-19 months and 24-27 months of age in children who had received a booster dose (HUU/2+1 and HUU/3+1 groups) than in the HUU/3+0 group. Carriage rates of NTHi, Staphylococcus aureus and Moraxella catarrhalis were comparable between all groups. CONCLUSIONS: HIV infection or exposure did not seem to alter the effect of PHiD-CV on pneumococcal NPC in children during their first 2 years of life. NPC prevalence of vaccine-type pneumococci following vaccination series tended to be lower in children who had received a booster dose in comparison to those who had not.
引用
- Madhi SA, Moreira M, Koen A, et al. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa. Vaccine. 2020. PMID: 32035706. doi:10.1016/j.vaccine.2020.01.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。